Chemistry:14-Methyl-LSD

From HandWiki

14-Methyl-LSD, or 14-Me-LSD, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the lysergamide family related to the psychedelic drug lysergic acid diethylamide (LSD).[1] It is the derivative of LSD with a methyl group at the 14 position.[1]

The drug is a highly potent full agonist of the serotonin 5-HT2A receptor, with an EC50 of 0.5432 nM and an Emax of 100.5% in an IP-1 assay.[1] Conversely, it is a very weak partial agonist or antagonist of the serotonin 5-HT2B receptor, with an EC50 of 2.319 nM and an Emax of 9.838% in an IP-1 assay.[1]

The chemical synthesis of 14-methyl-LSD has been described.[1] The drug's 2-bromo derivative, 2-Br-14-Me-LSD, has also been described.[1] It is a potent serotonin 5-HT2A receptor agonist similarly to 14-methyl-LSD, but with reduced potency and efficacy in comparison.[1] According to the compounds' developers, 14-methyl-LSD may produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, whereas 2-Br-14-Me-LSD may not produce the head-twitch response.[1]

14-Methyl-LSD was described by David E. Nichols and colleagues in association with 2A Biosciences as a key compound in a patent in 2025.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Nichols DE, Smith, "Substituted ergolines", WO patent 2025019454, published 23 January 2025, assigned to 2A Biosciences Incand Florida State University Research Foundation



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:14-Methyl-LSD&oldid=4433328"